Neumora Therapeutics extends drop after listless debut

Neumora Therapeutics

18/09/2023 14:46

** Shares of drug developer Neumora Therapeutics  NMRA.O 
fall 3.1% to $15.75
    ** Debuted at $16.50 on the Nasdaq on Friday, below offer
price of $17 apiece
    ** The lukewarm debut of Neumora, backed by Japan's SoftBank
 9984.T  and Amgen  AMGN.O , comes after SoftBank-owned chip
designer Arm Holdings  ARM.O  soared in its debut
    ** NMRA's lead product navacaprant, an investigational
once-daily oral medication, is in late-stage trials as a
potential monotherapy treatment for major depressive disorder


 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))